AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
argenx Q3 2025: $1.13B in Global Product Net Sales, VYVGART Expansion Plans, and Five Registrational Study Readouts in 2026
ByAinvest
Thursday, Oct 30, 2025 2:02 am ET1min read
argenx reported $1.13 bln in Q3 global product net sales, a YoY increase of $554 mln and a QoQ increase of $178 mln. The company is on track to submit an sBLA for seronegative gMG by year-end and expects to report ADAPT-OCULUS results in 1H26. Five registrational study readouts are expected in 2026 from its leading immunology pipeline.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet